Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2015 | Optimizing proteasome inhibitors for the treatment of multiple myeloma

At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel proteasome inhibitors in clinical development that have shown promising activity for the treatment of multiple myeloma. Rationally based combination therapies involving proteasome inhibitors may offer a new option to overcome drug resistance.